C4 Imaging LLC

Contact: Andrew Bright  
Location: Doylestown, PA  
Email: abright@c4imaging.com  
Tel: 609.933.5895  
Website: http://www.c4imaging.com

Company Profile

Industry Sector: Medical Devices

Company Overview: C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate image-guided procedures. The company’s proprietary technology, C4, was developed and patented at the MD Anderson Cancer Center; it is exclusively licensed to C4 Imaging. C4 is a unique MRI agent that has been encapsulated within an implantable, biocompatible shell. C4 Imaging has received FDA approval for an MRI Marker indicated in prostate cancer treatment and is now developing expanded clinical applications in other disease areas, utilizing additional imaging modalities (CT and ultrasound). The current development focus is a multi-modality breast biopsy site marker.

Target Market(s): Diagnostic radiology and surgical breast oncology departments of major US hospitals

Key Value Drivers

Technology*: C4 Imaging’s multi-modality breast biopsy site marker consists of a small, sealed polymer capsule containing a cobalt solution and a radio-opaque material. The properties of cobalt allow it to be viewed as a positive signal under MRI. Radio-opaque material allows it to be X-ray and CT visible.

Competitive Advantage: C4 Imaging’s non-metallic, artifact-free, multi-modality marker is better viewed on MRI. It eliminates the critical limitation placed by current markers on the utility of MRI in treatment planning, re-biopsy or re-screening patients. Standard metallic-core breast biopsy site markers are placed after the removal of a tissue sample. MRI artifacts associated with metallic cores limit MRI assessment of the extent of tumor when planning treatment and can prevent accurate MRI localization during re-biopsy.

Plan & Strategy: Launch with established breast market partner; Evaluate strategic investors or licensing partners, as well as engage acquisition partners.

Management

Leadership:
Andrew Bright, President and CEO  
Steven J. Frank, MD, Founder, Chairman of the Board  
Karen Martirosyan, PhD, Co-founder, CTO  
Harry Maziar, Board Member, Private Investor  
Steven Sheldon, CFA, Board Member, Private Investor  
Jim Webster, CFA, Advisory Board Member

Product Pipeline

2015  
Prostate brachytherapy marker

2016  
Gynecological and prostate HDR brachytherapy planning marker

2016  
Skin surface radiotherapy marker

2017  
Breast biopsy marker  
MR/LINAC targeting marker

2017  
Drug application development

2018+  
External beam radiotherapy and proton targeting marker